{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:13:59Z","timestamp":1788869639388,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T00:00:00Z","timestamp":1303171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      The efficacy, tolerability, and safety of the prophylactic treatment of hepatitis C virus (HCV) after liver transplantation (LT) with peginterferon alfa-2a and ribavirin are not known. LT recipients with HCV were randomized to peginterferon alfa-2a\/ribavirin treatment or observation 10 to 26 weeks post-LT. Prophylaxis patients received peginterferon alfa-2a (135 \u03bcg\/week for 4 weeks and then 180 \u03bcg\/week for 44 weeks) plus ribavirin (the initial dose of 400 mg\/day was escalated to 1200 mg\/day). Observation patients received the same regimen only upon significant HCV recurrence (histological activity index \u2265 3 and\/or fibrosis score \u2265 2). The primary endpoint was the proportion of patients with histological evidence of significant HCV recurrence 120 weeks after randomization. In all, 115 patients were randomized (prophylaxis arm, n = 55; observation arm, n = 60). Sustained virological response was achieved by 12 of 54 prophylaxis patients (22.2%) and by 3 of 14 observation patients who switched to treatment (21.4%). On an intent-to-treat basis, significant HCV recurrence at 120 weeks was similar in the prophylaxis (61.8%) and observation arms (65.0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.725). The patient and graft survival rates and the rates of biopsy-proven acute cellular rejection were similar in the 2 study arms. Approximately 70% of the treated patients in both arms had at least one dose reduction for safety reasons. The most common adverse event leading to treatment withdrawal was anemia. Because of the safety profile of peginterferon alfa-2a\/ribavirin and the lack of a clear benefit in terms of HCV recurrence and patient or graft survival, this study does not support the routine use of prophylactic antiviral therapy. Liver Transpl 17:528-538, 2011. \u00a9 2011 AASLD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/lt.22271","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T11:32:58Z","timestamp":1295004778000},"page":"528-538","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":88,"title":["PHOENIX"],"prefix":"10.1097","volume":"17","author":[{"given":"Natalie","family":"Bzowej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Everson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen L.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20250124","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.lts.2003.09.018","article-title":"Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.","volume":"9","author":"Adam","year":"2003","journal-title":"Liver Transpl"},{"key":"R2-7-20250124","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation.","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"R3-7-20250124","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.510290412","article-title":"Recurrent and new hepatitis C virus infection after liver transplantation.","volume":"29","author":"Everhart","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R4-7-20250124","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.","volume":"42","author":"Everson","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R5-7-20250124","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.20560","article-title":"Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.","volume":"41","author":"Chalasani","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R6-7-20250124","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jhep.2006.12.017","article-title":"A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.","volume":"46","author":"Angelico","year":"2007","journal-title":"J Hepatol"},{"key":"R7-7-20250124","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"R8-7-20250124","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","article-title":"Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.","volume":"40","author":"Dumortier","year":"2004","journal-title":"J Hepatol"},{"key":"R9-7-20250124","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/lt.20883","article-title":"Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.","volume":"12","author":"Fernandez","year":"2006","journal-title":"Liver Transpl"},{"key":"R10-7-20250124","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0041-1345(03)00446-9","article-title":"Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study.","volume":"35","author":"Mukherjee","year":"2003","journal-title":"Transplant Proc"},{"key":"R11-7-20250124","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1478-3231.2006.01261.x","article-title":"Impact of pegylated interferon -2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.","volume":"26","author":"Mukherjee","year":"2006","journal-title":"Liver Int"},{"key":"R12-7-20250124","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/jlts.2002.33968","article-title":"Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.","volume":"8","author":"Narayanan Menon","year":"2002","journal-title":"Liver Transpl"},{"key":"R13-7-20250124","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/01.TP.0000129811.93072.1C","article-title":"Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.","volume":"78","author":"Neff","year":"2004","journal-title":"Transplantation"},{"key":"R14-7-20250124","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1600-6143.2006.01470.x","article-title":"Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin.","volume":"6","author":"Oton","year":"2006","journal-title":"Am J Transplant"},{"key":"R15-7-20250124","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","article-title":"Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon 2b and ribavirin: an open-label series.","volume":"77","author":"Rodriguez-Luna","year":"2004","journal-title":"Transplantation"},{"key":"R16-7-20250124","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1399-0012.2003.00145.x","article-title":"Pegylated interferon -2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.","volume":"18","author":"Ross","year":"2004","journal-title":"Clin Transplant"},{"key":"R17-7-20250124","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1053\/jlts.2003.50255","article-title":"Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation.","volume":"9","author":"Terrault","year":"2003","journal-title":"Liver Transpl"},{"key":"R18-7-20250124","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.","volume":"8","author":"Veldt","year":"2008","journal-title":"Am J Transplant"},{"key":"R19-7-20250124","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/jlts.2002.31748","article-title":"A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.","volume":"8","author":"Crippin","year":"2002","journal-title":"Liver Transpl"},{"key":"R20-7-20250124","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"R21-7-20250124","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.23340","article-title":"Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.","volume":"51","author":"Bruno","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R22-7-20250124","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R23-7-20250124","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis. An update on terminology and reporting.","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R24-7-20250124","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.humpath.2006.08.028","article-title":"Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients.","volume":"38","author":"Khettry","year":"2007","journal-title":"Hum Pathol"},{"key":"R25-7-20250124","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transpl"},{"key":"R27-7-20250124","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-6143.2004.00648.x","article-title":"Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.","volume":"5","author":"Shergill","year":"2005","journal-title":"Am J Transplant"},{"key":"R28-7-20250124","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.","volume":"6","author":"Wang","year":"2006","journal-title":"Am J Transplant"},{"key":"R29-7-20250124","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1600-6143.2009.02702.x","article-title":"A practical guide to the management of HCV infection following liver transplantation.","volume":"9","author":"Watt","year":"2009","journal-title":"Am J Transplant"},{"key":"R30-7-20250124","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.","volume":"38","author":"Davis","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R31-7-20250124","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)ribavirin.","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"R32-7-20250124","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/lt.20189","article-title":"Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.","volume":"10","author":"Stravitz","year":"2004","journal-title":"Liver Transpl"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22271","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201105000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T12:06:00Z","timestamp":1737720360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201105000-00007"}},"subtitle":["A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus"],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22271","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}